Toi M, Bando H, Kuroi K
Tokyo Metropolitan Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan.
Breast Cancer. 2000;7(4):311-4. doi: 10.1007/BF02966396.
Recent accumulated data have indicated that angiogenesis is a promising indicator to predict prognosis and response to treatment. In breast cancer, microvessel density (MVD), a semi-quantitative marker of neovascularization grade, has been suggested to provide independent prognostic value. In addition, the expression of both vascular endothelial growth factor (VEGF)and thymidine phosphorylase (TP), two angiogenesis regulatory molecules, were found to be closely associated with MVD, and with the effect of treatments. In particular, VEGF expression seems to be a phenotype resistant to endocrine therapy, whereas TP expression decreases sensitivity to chemotherapy containing fluorouracil. This review summarizes the current topics regarding the prognostic and predictive value of angiogenesis in primary breast cancer, and we discuss future applications of antiangiogenesis treatments in an adjuvant setting.
最近积累的数据表明，血管生成是预测预后和治疗反应的一个有前景的指标。在乳腺癌中，微血管密度（MVD）作为新生血管形成分级的半定量标志物，已被认为具有独立的预后价值。此外，血管内皮生长因子（VEGF）和胸苷磷酸化酶（TP）这两种血管生成调节分子的表达，被发现与MVD以及治疗效果密切相关。特别是，VEGF表达似乎是一种对内分泌治疗耐药的表型，而TP表达则降低了对含氟尿嘧啶化疗的敏感性。本综述总结了关于原发性乳腺癌血管生成的预后和预测价值的当前主题，并讨论了抗血管生成治疗在辅助治疗中的未来应用。
